Diagnosis Archives – Treatment Action Group

TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis

March 17, 2023
Dorrit Walsh

Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

Roundtable on Access to Multi-disease Molecular Diagnostics

June 23, 2022
Dorrit Walsh

On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…

cover of publication: An Advocate's Introduction to SARS-CoV-2 Rapid Diagnostic Testing, there's a drawing on the cover of a hand holding up two types of COVID rapid tests

Test and Treat COVID-19: An Advocate’s Introduction to SARS-CoV-2 Rapid Diagnostic Testing

June 7, 2022
Dorrit Walsh

All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on interventions such as self-isolation, contact tracing, and antiviral treatment.

Community-led Monitoring for Access to Tuberculosis Screening and Diagnostic Testing

April 7, 2022
Dorrit Walsh

People at risk of tuberculosis (TB) have a right to TB screening and diagnostic testing in accordance with the standard of care recommended by the World Health Organization (WHO). Yet, many countries with high burdens of TB have limited uptake…

Statement from TAG’s TB Project on Today’s WHO Global TB Report

October 14, 2021
Dorrit Walsh

Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.

first page of TAG and MSF brief: Realizing returns on U.S. government investment in GeneXpert Diagnostic Technologies

Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies

September 15, 2021
Dorrit Walsh

GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs

May 10, 2021
Dorrit Walsh

The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Demanding a Higher Standard of TB Care

September 2, 2020
Dorrit Walsh

In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.